Kezar Life Sciences: positive PORTOLA Phase 2a data; steroid-sparing remissions in AIH, cash $132M

Kezar Life Sciences, Inc.

31% of zetomipzomib patients achieved CR + steroid taper ≤5 mg/day vs 12.5% placebo in ITT (n=24).
In steroid-dependent subgroup, 36% zetomipzomib CR + taper ≤5 mg/day vs 0% placebo; median response 27.6 weeks.
No Grade 4/5 AEs; injection site reactions most common; one placebo SAE (variceal bleed), two zetomipzomib SAEs (fever, flu).
FY2024 net loss $83.7M vs $101.9M in 2023; cash $132.2M at Dec 31, 2024.
Company plans to discuss with FDA to remove partial clinical hold and design registrational trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.